title: [Studies of damaged processes in the nervous system and possibilities of neuroprotection].
abstract: The paper presents the results of experimental studies and clinical trials associated with mechanism underlying nervous system damage and pharmacological interventions to be employed in such processes. Abnormal lipid peroxidation was demonstrated in experimental seizures, epilepsy and cerebral stroke. The authors presented the mechanism of calcium channel blockers activity in epilepsy and their experience in employing such agents in epileptic patients. Results of studies on S-100 protein determinations as a marker of the blood-brain barrier damage in epilepsy and hydrocephalus were discussed, along with the employment of evoked potentials in diagnostic management of headaches and the effects of complex treatment of epilepsy in children using Nootropil. Selected data on experimental valproate encephalopathy were also presented. The authors believe that these studies contribute to the understanding of mechanism that are responsible for nervous system dysfunction, as well as to the evaluation and treatment of their effects.
authors.affiliation: Klinika Neurologii Dzieciecej Akademii Medycznej w Białymstoku.
authors.forename: W
authors.initials: W
authors.lastname: Sobaniec
authors.forename: W
authors.initials: W
authors.lastname: Kułak
authors.forename: L
authors.initials: L
authors.lastname: Boćkowski
authors.forename: J
authors.initials: J
authors.lastname: Smigielska-Kuzia
authors.forename: M
authors.initials: M
authors.lastname: Sobaniec-Łotowska
authors.forename: E
authors.initials: E
authors.lastname: Sołowiej
authors.forename: H
authors.initials: H
authors.lastname: Sobaniec
authors.forename: B
authors.initials: B
authors.lastname: Artemowicz
mesh_terms: D000328:Adult; D000818:Animals; D015415:Biomarkers / Q000032:analysis; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002648:Child; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy; D005071:Evoked Potentials; D006801:Humans; D015227:Lipid Peroxidation; D009422:Nervous System Diseases / Q000175:diagnosis* / Q000188:drug therapy*; D010889:Piracetam / Q000627:therapeutic use; D009418:S100 Proteins / Q000032:analysis; D014635:Valproic Acid / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D002121:Calcium Channel Blockers; D009418:S100 Proteins; D014635:Valproic Acid; D010889:Piracetam